Compare Merck & Co., Inc. (MRK) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Financial Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $145.85 (market cap $351.28B), while Financial Select Sector SPDR Fund trades at $54.7 (market cap $50.06B). The key difference: Merck & Co., Inc. is far larger — about 7× Financial Select Sector SPDR Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| MRK | XLF | |
|---|---|---|
Market Cap | $351.28B | $50.06B |
Volume | 7,969,665 | 47,464,120 |
Sector | Health | — |
52-Week High | $156.43 | $58.55 |
52-Week Low | $82.49 | $47.80 |
Typical Hold Time | 98 Days | 104 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
XLF trades at $54.48, up 1.36% with a bearish technical signal from moving averages. The ETF faces headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The outlook remains cautious with technical indicators showing bearish momentum. Rising interest rates could benefit financial sector profitability, but regulatory uncertainty and market underperformance relative to broader indices present near-term risks for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
